Immunine (Human Coagulation Factor Ix)

• Immunine is a recombinant factor IX product that acts on the intrinsic coagulation pathway to manage bleeding disorders.
• Hemophilia B: restores clotting ability and reduces bleeding episodes.
• Acquired factor IX deficiency: provides the missing factor to achieve hemostasis.
• Peri‑operative management in factor IX‑deficient patients: lowers surgical bleeding risk.

• Human Coagulation Factor IX replaces the deficient endogenous factor IX in the intrinsic pathway of the coagulation cascade. By binding to activated factor VIII on phospholipid surfaces, it forms the tenase complex, which activates factor X to Xa, leading to thrombin generation and fibrin clot formation, thereby correcting the coagulation defect.

Adverse reactions may occur with any intravenous factor IX product.

Common Side Effects

• Infusion‑related reactions such as chills or fever.
• Headache.
• Nausea or vomiting.
• Arthralgia.
• Mild rash at the infusion site.
• Transient increase in blood pressure.

Serious or Rare Side Effects

• Anaphylactic or severe allergic reactions.
• Development of neutralizing antibodies (inhibitors) against factor IX.
• Thromboembolic events including deep vein thrombosis.
• Severe hypotension.
• Renal impairment or failure.
• Hemolysis.

• Before initiating therapy, clinicians should consider several safety measures.
• Dose adjustment: individualize based on measured factor IX activity levels.
• Monitoring: regularly assess coagulation parameters and clinical response.
• Allergy assessment: evaluate for hypersensitivity to human plasma‑derived proteins.
• Inhibitor surveillance: test for development of anti‑factor IX antibodies.
• Pregnancy and lactation: use only if the potential benefit justifies the potential risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Factor IX replacement can interact with other agents that affect hemostasis.

Major Interactions (Avoid)

• Antifibrinolytics: may increase thrombosis risk when combined with factor IX.
• Concurrent use of other clotting factor concentrates: risk of excessive clot formation.
• Activated prothrombin complex concentrates: additive pro‑coagulant effect.

Moderate Interactions (Monitor Closely)

• Certain antibiotics (e.g., aminoglycosides) that may affect renal clearance of the product.
• Immunosuppressive agents: may influence inhibitor development.
• Vaccinations: monitor for altered immune response when administered near factor IX infusions.